Potential effects of ursodeoxycholic acid on accelerating cutaneous wound healing - Fig 4
(A) TGF-β1 immune-stained wounded skin sections revealing; decreased expression in at zero-day(a), significant increased expression in non-treated (b) and in UDCA-treated (c) wounds 5 days post wounding. (B)MMP-2 immune-stained wounded skin sections’ revealing low immunopositivity at zero-day (a), significant increased immunopositivity in non-treated (b) and in UDCA-treated (c) wounds5 days post wounding. (C) NF-κB immune-stained wounded skin’ sections revealing; nil expression at zero-day(a), increased expression in the non-treated group(b) more than in the UDCA treated mice (c) at5 days post wounding. The quantitative image analysis, for TGF-β1, MMP-2 and NF-κB immune-staining expressed as optical densities (OD) across 5 different microscopic fields showing significant increased expression of TGF-β1 and MMP-2 with decreased the expression of NF-κB in UDCA-treated groups. *P<0.05, ***P < 0.001: significantly different from non-treated groups. UDCA: ursodeoxycholic acid.